| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 0 | 330 | 0 | 0 | 0 |
| Sales Growth | -100.00% | unch | unch | unch | -100.00% |
| Net Income | -18,410 | -18,390 | -14,290 | -19,140 | -17,120 |
| Net Income Growth | -0.11% | -28.69% | +25.34% | -11.80% | -41.02% |
Applied Genetic Tech (AGTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.
Fiscal Year End Date: 06/30